Crispr Therapeutics shares tumble after significant earnings miss
Fidus Investment Corp (NASDAQ:FDUS)'s stock reached a 52-week high this week, hitting $21.32, signaling a period of robust performance for the company. According to InvestingPro data, the company maintains an impressive 11.4% dividend yield and has maintained dividend payments for 14 consecutive years. This milestone reflects a significant uptrend from the previous year, with the stock delivering a 24.4% total return over the past 12 months. Investors have shown increased confidence in FDUS, buoyed by the company's strategic initiatives and strong financial results, including 19.6% revenue growth and an attractive P/E ratio of 7.7. The company's "GOOD" financial health score on InvestingPro and robust current ratio of 2.3 have collectively contributed to the stock's impressive climb to this new high-water mark.
In other recent news, Fidus Investment Corporation reported a robust growth in their Q3 earnings call. The company highlighted a 20% increase in its debt portfolio and a record interest income of $33.7 million. The net asset value also increased by 11.8% to $658.8 million. Adjusted net investment income saw a rise of 12.3% to $20.4 million, supporting dividends of $0.57 per share.
New investments for the quarter totaled $65.9 million, with the portfolio's fair value reaching $1.1 billion. In addition, Fidus secured a new SBIC license, providing access to an extra $175 million in debentures. Despite a slight decrease in the weighted average effective yield on debt investments to 13.8%, the company's liquidity remains strong with approximately $154.4 million available.
CEO Ed Ross anticipates an increase in M&A activity in Q4 2024 and an active investment quarter ahead. However, the company observed some credit migration issues and a slight increase in Grade 3 risk ratings. Despite these developments, Fidus remains optimistic about its equity portfolio and plans no major transactions in the near future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.